Please login to the form below
valsartan
This page shows the latest valsartan news and features for those working in and with pharma, biotech and healthcare.
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
The increase was driven by the strong performance of its heart failure combination Entresto (sacubitril/valsartan) which was up by 44%, psoriasis antibody Cosentyx (secukinumab) up by 22%, myelofibrosis drug Jakavi
Latest news
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
-
Novartis hit by ‘COVID-19-related lockdowns’ in Q4
added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
sacubitril/valsartan), which grew by 79% and 45% in the quarter, respectively.
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
This includes Novartis’ Entresto (sacubitril/valsartan) and AstraZeneca’s Farxiga (dapagliflozin) which have been steadily adding indications to their labels since initial approval.
-
Novartis stumbles in Q2 as COVID-19 impacts sales
Its psoriasis and arthritis drug Cosentyx (secukinumab) also saw a sales rise of 12% to $944m, while its heart failure drug Entresto (sacubitril/valsartan) climbed 40% to $508m.
More from news
Approximately 7 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
COVID-19 hits supply chains
High-profile examples include heparin, a blood thinner commonly used in hospitals, linked to 246 fatalities, and valsartan, a blood pressure drug found to be contaminated with a carcinogen once used ... The valsartan recall was particularly dismaying
-
20 for 2020 – Five pharma leaders to watch in 2020
Entresto (valsartan/sacubitril).
-
Heart failure therapy embarks on a new era
combines the long-established ARB valsartan with sacubitril - a first-in-class neprilysin inhibitor.
-
Country report: The healthcare market in Japan
Diovan. valsartan. Novartis. Hypertension. 4. Cervarix. human papillomavirus (HPV) vaccine. GlaxoSmithKline.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- A creative awakening – how pharma is bringing innovation to the patient journey
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Shionogi Europe and NHS England agree on antibiotic subscription model
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
